Graduate School of Life Sciences
Refine
Is part of the Bibliography
- yes (1034)
Year of publication
Document Type
- Doctoral Thesis (1024)
- Journal article (9)
- Book (1)
Language
- English (803)
- German (230)
- Multiple languages (1)
Keywords
- Maus (38)
- Thrombozyt (33)
- T-Lymphozyt (30)
- Tissue Engineering (29)
- Taufliege (21)
- Dendritische Zelle (19)
- Genexpression (18)
- Myc (17)
- Angst (16)
- Entzündung (16)
Institute
- Graduate School of Life Sciences (1034)
- Theodor-Boveri-Institut für Biowissenschaften (101)
- Rudolf-Virchow-Zentrum (70)
- Medizinische Fakultät (44)
- Institut für Pharmakologie und Toxikologie (39)
- Institut für Virologie und Immunbiologie (35)
- Institut für Psychologie (34)
- Institut für Molekulare Infektionsbiologie (33)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (29)
- Julius-von-Sachs-Institut für Biowissenschaften (25)
Sonstige beteiligte Institutionen
- Helmholtz Institute for RNA-based Infection Research (HIRI) (7)
- Universitätsklinikum Münster (3)
- Rudolf Virchow Center for Integrative and Translational Bioimaging, University of Würzburg (2)
- Zentrum für Infektionsforschung (ZINF) Würzburg (2)
- Bio-Imaging Center Würzburg (1)
- Biomedical Center Munich, Department of Physiological Chemistry, Ludwig-Maximilians-Universität München (1)
- CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - the development agency of the Brazilian Federal Government (1)
- CBIO, University of Cape Town, South Africa (1)
- Carl-Ludwig-Institut für Physiologie, Universität Leipzig (1)
- Chair of Experimental Biomedicine I (1)
Oncolytic viral therapies have shown great promise pre-clinically and in human clinical trials for the treatment of various cancers. Oncolytic viruses selectively infect and replicate in cancer cells, destroying tumor tissue via cell lysis, while leaving noncancerous tissues unharmed. Vaccinia virus (VACV) is arguably one of the safest viruses, which has been intensively studied in molecular biology and pathogenesis as a vaccine for the eradication of smallpox in more than 200 million people. It has fast and efficient replication, and cytoplasmic replication of the virus lessens the chance of recombination or integration of viral DNA into the genome of host cells. Anti-tumor therapeutic efficacy of VACV has been demonstrated for human cancers in xenograft models with a variety of tumor types. In addition recombinant oncolytic VACVs carrying imaging genes represent an advance in treatment strategy that combines tumor-specific therapeutics as well as diagnostics.
As for other targeted therapies, a number of challenges remain for the clinical translation of oncolytic virotherapy. These challenges include the potential safety risk of replication of oncolytic virus in non-tumor tissue, the relatively poor virus spread throughout solid tumor tissue and the disadvantageous ratio between anti-viral and anti-tumoral immunity. However, manipulation of components of the tumor microenvironment may help oncolytic virus infection in killing the tumor tissue and thereby increasing the anti-tumor efficacy. Furthermore, dogs with natural cancer are considered as one of the best animal models to develop new drugs for cancer therapy. Traditionally, rodent cancer models have been used for development of cancer therapeutics. However, they do not adequately represent several features that define cancer in humans, including biology of initiation of tumor, the complexity of cancer recurrence and metastasis and outcomes to novel therapies. However, the tumor microenvironment, histopathology, molecular and genomics data from dog tumors has significant similarities with corresponding human tumors. These advantages of pet dog cancers provide a unique opportunity to integrate canine cancer patients in the studies designed for the development of new cancer drugs targeted against both human and canine cancers. This dissertation centers on the use of VACV strains in canine cancer xenografts with the aim of understanding the effects of modulation of tumor microenvironment on VACV-mediated tumor therapy.
In the first studies, wild-type VACV strain LIVP6.1.1 was tested for its oncolytic efficiency in canine soft tissue sarcoma (STSA-1) and canine prostate carcinoma (DT08/40) cells in culture and xenografts models. LIVP6.1.1 infected, replicated within, and killed both STSA-1 and DT08/40 cells in cell culture. The replication of virus was more efficient in STSA-1 cells compared to DT08/40 cells. In xenograft mouse models, LIVP6.1.1 was safe and effective in regressing both STSA-1 and DT08/40 xenografts. However, tumor regression was faster in STSA-1 xenografts compared to DT08/40 xenografts presumably due to more efficient replication of virus in STSA-1 cells. Biodistribution profiles revealed persistence of virus in tumors 5 and 7 weeks post virus injection in STSA-1 and DT08/40 xenografts, respectively, with the virus mainly cleared from all other major organs. Immunofluorescence staining detected successful colonization of VACV in the tumor. Consequently, LIVP6.1.1 colonization in the tumor showed infiltration of innate immune cells mainly granulocytes and macrophages in STSA-1 tumor xenografts. These findings suggest that virotherapy-mediated anti-tumor mechanism in xenografts could be a combination of direct viral oncolysis of tumor cells and virus-dependent infiltration of tumor-associated host immune cells.
In further studies, the effects of modulation of tumor angiogenesis of VACV therapy were analyzed in canine cancer xenografts. GLV-1h109 VACV strain (derived from prototype virus GLV-1h68) encoding the anti-VEGF single chain antibody GLAF-1 was characterized for its oncolytic efficacy in STSA-1 and DT08/40 cancer cells in culture and tumor xenografts. Concomitantly, the effects of locally expressed GLAF- 1 in tumors on virus replication, host immune infiltration, tumor vascularization and tumor growth were also evaluated.
GLV-1h109 was shown to be similar to the parental virus GLV-1h68 in expression of the two marker genes that both virus strains have in common (Ruc-GFP and gusA) in cell cultures. Additionally, the anti-VEGF single-chain antibody GLAF-1 was expressed by GLV-1h109 in both cell cultures and tumor xenografts. The insertion of GLAF-1 did not significantly affect the replication and cytotoxicity of GLV-1h109 in the STSA-1 and DT08/40 cell lines, although at early time points (24-48 hpi), the replication of GLV-1h109 was higher in STSA-1 cells compared to DT08/40 cells. In addition, STSA-1 cells were more susceptible to lysis with GLV-1h109 than DT08/40 cells. GLV-1h109 achieved a significant inhibition of tumor growth in both STSA-1 and DT08/40 canine xenografts models. Consequently, the significant regression of tumor growth was initiated earlier in STSA-1 tumor xenografts compared to regression in DT08/40 xenografts. The reason for the higher efficacy of GLV-1h109 in STSA-1 xenografts than DT08/40 xenografts was attributed to more efficient replication of virus in STSA-1 cells. In addition, tumor-specific virus infection led to a continued presence of GLAF-1 in peripheral blood, which could be useful as a pharmacokinetic marker to monitor virus colonization and persistence in GLV-1h109- injected xenograft mice. GLAF-1 is a single-chain antibody targeting human and murine VEGF. It was demonstrated that GLAF-1 was functional and recognized both canine and human VEGF with equal efficiency.
Histological analysis of tumor sections 7 days after GLV-1h109 injection confirmed that colonization of VACV and intratumoral expression of GLAF-1 translated into a significant decrease in blood vessel number compared to GLV-1h68 or PBS-treated control tumors. Subsequently, reduction in blood vessel density significantly improved the spread and replication of VACV as observed by FACS analysis and standard plaque assay, respectively. Inhibition of tumor angiogenesis and increased replication of virus further improved the infiltration of innate immune cells mainly granulocytes and macrophages in STSA-1 tumor xenografts. Both the results, i.e. improved virus spread and increased infiltration of innate immune cells in tumor, were explained by a phenomenon called “vascular normalization”, where anti-VEGF therapy normalizes the heterogeneous tumor vasculature thereby improving delivery and spread of VACV. In summary, the effects of inhibition of tumor angiogenesis on virus spread and replication were demonstrated using a vaccinia virus caring an anti- angiogenic payload targeting vascular endothelial growth factor (VEGF) in canine cancer xenografts.
In the final studies, the effects of VACV therapy on modulation of the immune system were analyzed in canine cancer patients enrolled in a phase I clinical trial. V-VET1 (clinical grade LIVP6.1.1 VACV) injection significantly increased the percentages of CD3+CD8+ T lymphocytes at 21 days after initiation of treatment. CD3+CD8+ T lymphocytes are mainly cytotoxic T lymphocytes that have potential to lyse cancer cells. Subsequently, the frequency of immune suppressor cells, mainly MDSCs and Treg was also analyzed in peripheral blood of canine cancer patients. Increase in the MDSC population and decreased CD8/Treg ratio is known to have inhibitory effects on the functions of cytotoxic T cells. We demonstrated that injection of V-VET1 in canine cancer patients significantly reduced the percentages of MDSCs at 21 days post initiation of treatment. Additionally, CD8/Treg ratio was increased 21 days after initiation of V-VET1 treatment. We also showed that changes in the frequency of immune cells neither depends on dose of virus nor depends on tumor type according to the data observed from this clinical trial with eleven analyzed patients.
This preclinical and clinical data have important clinical implications of how VACV therapy can be used for the treatment of canine cancers. Moreover, dogs with natural cancers can be used as an ideal animal model to improve the oncolytic virotherapy for human cancers. Furthermore, modulation of tumor microenvironment mainly tumor angiogenesis and tumor immunity has significant impact on the success of oncolytic virotherapy.
Besides HIV and tuberculosis, malaria still is one of the most devastating infectious diseases especially in developing countries, with Plasmodium falciparum being responsible for the frequently lethal form of malaria tropica. It is a major cause of mortality as well as morbidity, whereby pregnant women and children under the age of five years are most severely affected. Rapidly emerging drug resistances and the lack of an effective and safe vaccine hamper the combat against malaria by chemical and pharmacological regimens, and moreover the poor socio-economic and healthcare conditions in malaria-endemic countries are compromising the extermination of this deadly tropical disease to a large extent. Malaria research is still questing for druggable targets in the parasitic protozoan which pledge to be refractory against evolving resistance-mediating mutations and yet constitute affordable and compliant antimalarial chemotherapeutics.
The parasite kinome consists of members that represent most eukaryotic protein kinase groups, but also contains several groups that can not be assigned to conservative ePK groups. Moreover, given the remarkable divergence of plasmodial kinases in respect to the human host kinome and the fact that several plasmodial kinases have been identified that are essential for the intraerythrocytic developmental cycle, these parasite enzymes represent auspicious targets for antimalarial regimens. Despite elaborate investigations on several other ePK groups, merely scant research has been conducted regarding the four identified members of the cyclin-dependent kinase-like kinase (CLK) family, PfCLK-1-4. In other eukaryotes, CLKs are involved in mRNA processing and splicing by means of phosphorylation of serine/arginine-rich (SR) proteins, which are crucial components of the splicing machinery in the alternative splicing pathway. All four PfCLKs are abundantly expressed in asexual parasites and gametocytes, and stage-specific expression profiles of PfCLK-1 and PfCLK-2 exhibited nucleus-associated localization and an association with phosphorylation activity. In the course of this study, PfCLK-3 and PfCLK-4 were functionally characterized by indirect immunofluorescence, Western blot analysis and kinase activity assays. These data confirm that the two kinases are primarily expressed in the nucleus of trophozoites and both kinases possess in vitro phosphorylation activity on physiological substrates. Likewise PfCLK-1 and PfCLK-2, reverse genetic studies exhibited the indispensability of both PfCLKs on the asexual life cycle of P. falciparum, rendering them as potential candidates for antiplasmodial strategies. Moreover, this study was conducted to identify putative SR proteins as substrates of all four PfCLKs. Previous alignments revealed a significant homology of the parasite CLKs to yeast SR protein kinase Sky1p. Kinase activity assays showed in vitro phosphorylation of the yeast Sky1p substrate and SR protein Npl3p by precipitated PfCLKs. In addition, four homologous plasmodial SR proteins were identified that are phosphorylated by PfCLKs in vitro: PfASF-1, PFSRSF12, PfSFRS4 and PfSR-1. All four parasite SR splicing factors are predominantly expressed in the nuclei of trophozoites. For PfCLK-1, a co-localization with the SR proteins was verified.
Finally, a library of human and microbial CLK inhibitors and the antiseptic chlorhexidine (CHX) was screened to determine their inhibitory effect on different parasite life cycle stages and on the PfCLKs specifically. Five inhibitors out of 63 compounds from the investigated library were selected that show a moderate inhibition on asexual life cycle stages with IC50 values ranging between approximately 4 and 8 µM. Noteworthy, these inhibitors belong to the substance classes of aminopyrimidines or oxo-β-carbolines. Actually, the antibiotic compound CHX demonstrated an IC50 in the low nanomolar range. Stage-of-inhibition assays revealed that CHX severely affects the formation of schizonts. All of the selected CLKs inhibitors also affect gametocytogenesis as well as gametogenesis, as scrutinized in gametocyte toxicity assays and exflagellation assays, respectively. Kinase activity assays confirm a specific inhibition of CLK-mediated phosphorylation of all four kinases, when the CLK inhibitors are applied on immunoprecipitated PfCLKs. These findings on PfCLK-inhibiting compounds are initial attempts to determine putative antimalarial compounds targeting the PfCLKs. Moreover, these results provide an effective means to generate chemical kinase KOs in order to phenotypically study the role of the PfCLKs especially in splicing events and mRNA metabolism. This approach of functionally characterizing the CLKs in P. falciparum is of particular interest since the malarial spliceosome is still poorly understood and will gain further insight into the parasite splicing machinery.
The role of human Ephrin receptor tyrosine kinase A2 (EphA2) in Chlamydia trachomatis infection
(2015)
Chlamydia trachomatis (Ctr), an obligate intracellular gram negative human pathogen, causes sexually transmitted diseases and acquired blindness in developing countries. The infectious elementary bodies (EB) of Ctr involved in adherence and invasion processes are critical for chlamydial infectivity and subsequent pathogenesis which requires cooperative interaction of several host cell factors. Few receptors have been known for this early event, yet the molecular mechanism of these receptors involvement throughout Ctr infection is not known. Chlamydial inclusion membrane serves as a signaling platform that coordinates Chlamydia-host cell interaction which encouraged me to look for host cell factors that associates with the inclusion membrane, using proteome analysis. The role of these factors in chlamydial replication was analyzed by RNA interference (RNAi) (in collaboration with AG Thomas Meyer). Interestingly, EphrinA2 receptor (EphA2), a cell surface tyrosine kinase receptor, implicated in many cancers, was identified as one of the potential candidates. Due to the presence of EphA2 in the Ctr inclusion proteome data, I investigated the role of EphA2 in Ctr infection. EphA2 was identified as a direct interacting receptor for adherence and entry of C. trachomatis. Pre-incubation of Ctr-EB with recombinant human EphA2, knockdown of EphA2 by siRNA, pretreatment of cells with anti-EphA2 antibodies or the tyrosine kinase inhibitor dasatinib significantly reduced Ctr infection. This marked reduction of Ctr infection was seen with both epithelial and endothelial cells used in this study. Ctr activates EphA2 upon infection and invades the cell together with the activated EphA2 receptor that interacts and activates PI3K survival signal, promoting chlamydial replication. EphA2 upregulation during infection is associated with Ctr inclusion membrane inside the cell and are prevented being translocated to the cell surface. Ephrins are natural ligands for Ephrin receptors that repress the activation of the PI3K/Akt pathway in a process called reverse signaling. Purified Ephrin-A1, a ligand of EphA2, strongly interferes with chlamydial infection and normal development, supporting the central role of these receptors in Chlamydia infection. Overexpression of full length EphA2, but not the mutant form lacking the intracellular cytoplasmic domain, enhanced PI3K activation and Ctr infection. Ctr infection induces EphA2 upregulation and is mediated by activation of ERK signaling pathway. Interfering with EphA2 upregulation sensitizes Ctr-infected cells to apoptosis induced by tumor necrosis factor-alpha (TNF-α) suggesting the importance of intracellular EphA2 signaling.
Collectively, these results revealed the first Ephrin receptor “EphA2” that functions in promoting chlamydial infection. In addition, the engagement of a cell surface receptor at the inclusion membrane is a new mechanism how Chlamydia subverts the host cell and induces apoptosis resistance. By applying the natural ligand Ephrin-A1 and targeting EphA2 offers a promising new approach to interfere with Chlamydia infection. Thus, the work provides the evidence for a host cell surface tyrosine kinase receptor that is exploited for invasion as well as for receptor-mediated intracellular signaling to facilitate the chlamydial replication.
Leishmaniasis is a neglected tropical disease that can be manifested through different clinical forms, ranging from cutaneous to visceral. The host response against Leishmania spp. is greatly dependent on T cell-mediated immunity, in which T helper 1 responses are associated with macrophage activation and elimination of the parasite, while regulatory T cells and T helper 2 responses are correlated with parasite survival and persistence of infection. Leishmania uses different virulence factors as strategies for evading the immune response of the host. One of them are cathepsin-like cysteine proteases, which are currently under extensive investigation as targets for drug development. Previous studies with inhibitors of cathepsins B and L in vivo revealed an outstanding modulation of the host T helper cell response. However, the mechanisms behind these observations were not further investigated. Given the urgent need for better treatments against leishmaniasis, the aim of this study was to investigate the effects that the lack of cathepsin B and L activity have on the signals that dendritic cells use to instruct T helper cell polarization in response to infection with Leishmania major.
The cathepsin inhibitors tested showed low or no cytotoxicity in bone marrow-derived dendritic cells, and dendritic cells and macrophages could be generated from cathepsin B and cathepsin L-deficient mice without apparent alterations in their phenotype in comparison to wild-type controls. Furthermore, lack of cathepsin B and L activity showed no impact in the rate of promastigote processing by dendritic cells. Cathepsin B and cathepsin L-deficient macrophages showed no differences in parasite proliferation and capacity to produce nitric oxide in comparison to wild-type macrophages. In response to the parasite, dendritic cells treated with a cathepsin B inhibitor and dendritic cells from cathepsin B-deficient mice showed higher levels of expression of major histocompatibility complex (MHC) class II molecules than dimethyl sulfoxide (DMSO) or wild-type controls, but it was not accompanied by changes in the expression of costimulatory molecules. Wild-type dendritic cells and macrophages are not able to express the pro-inflammatory cytokine interleukin (IL)-12 in response to promastigotes. However, cells treated with a cathepsin B inhibitor or cells deficient for cathepsin B were able to express IL-12, whilethe expression of other cytokines -including IL-6 and tumor necrosis factor (TNF)-alpha-remained unchanged. These characteristics point towards a more “pro-Th1” profile of dendritic cells in the absence of cathepsin B.
This data is the first report on IL-12 regulation depending on cathepsin B. The IL-12 up-regulation observed was already present at the transcriptional level. Furthermore, it was also present in macrophages and dendritic cells in response to LPS, and the latter had a higher capacity to induce T cell helper 1 polarization in vitro than wild-type dendritic cells. The activation of different signaling pathways was analyzed, but the up-regulation of IL-12 could not be attributed to modulation of nuclear factor-kappaB (NFkappaB), p38 mitogen activated protein kinase (MAPK) and extra-cellular signal-regulated kinase (ERK)1/2 pathways. Thus, the mechanism behind IL-12 regulation by cathepsin B remains to be elucidated, and the impact of these effects is yet to be confirmed in vivo. Altogether it is tempting to speculate that cathepsin B, in addition to its role in processing endocytosed material, is involved in the modulation of the pro-inflammatory cytokine IL-12.
E. coli Nissle 1917 (EcN) zählt durch seine fast hundertjährige Nutzung als Arzneimittel und aufgrund der weitreichenden Forschung während der letzten Jahrzehnte mittlerweile zu einem der am besten untersuchten Probiotika. EcN wird als Medikament zur Remissionserhaltung von Patienten mit Kolitis, bei chronischer Verstopfung und bei Durchfall von Kleinkindern eingesetzt.
Der enteroaggregative – hämorrhagische - E. coli (EAHEC) mit dem Serotyp O104:H4 war 2011 in Deutschland für den bisher größten EHEC-Ausbruch seit Beginn der Aufzeichnungen verantwortlich. Es fehlt bis zum heutigen Tage immer noch an effektiven Möglichkeiten einer Infektionsprophylaxe oder einer Behandlung der Erkrankung. Ein alternatives Therapeutikum wird daher dringend benötigt. In dieser Arbeit wurden die antagonistischen Effekte von EcN auf pathogene E. coli Stämme wie dem EHEC Stamm EDL933 oder klinischen EAHEC O104:H4 Isolaten untersucht. Es wurden die Auswirkungen von EcN auf die Adhäsion an humane Epithelzellen, das Wachstum und die Shiga Toxin Produktion der pathogenen Stämme untersucht. Zusätzlich wurde die Resistenz von EcN gegenüber Shiga Toxin Phagen nachgewiesen.
Zunächst wurde die Adhäsionseffizienz der verschiedenen E. coli Stämme bestimmt. Der am schlechtesten an die humanen Epithelzelllinien Caco-2 und LS-174T adhärierende Stamm war EcN. Dies ist insofern überraschend, da von Probiotika erwartet wird, besser als Pathogene an Epithelzellen zu adhärieren. Dem ungeachtet konnte jedoch gezeigt werden, dass EcN die Adhäsion von zwei EAHEC O104:H4 Isolaten, des nahe verwandten enteroaggregativen E. coli (EAEC) Stammes 55989 und des enterohämorrhagischen (EHEC) E. coli Stammes O157:H7 EDL933 an beide Zelllinen hemmt. Die von EcN produzierten Mikrozine M und H47 konnten hier für einen Teil des beobachteten anti-adhäsiven Effektes von EcN auf die pathogenen E. coli Stämme verantwortlich gemacht werden. Die Mikrozine wurden hier als einzige Substanz, die das Wachstum der pathogenen E. coli Stämme beeinflusst, identifiziert.
Einer der wichtigsten Virulenzfaktoren von EAHEC und EHEC Stämmen ist das Shiga Toxin. In dieser Arbeit konnte gezeigt werden, dass EcN die Shiga Toxin Produktion der am häufigsten auftretenden EHEC Stämme (´Big Five´: O157:H7, O26:H11, O103:H2, O111:H-, O145:H25) und der klinischen Isolate von EAHEC O104:H4 im Zellkulturmedium DMEM hemmt.
Auffällig war, dass die Stx1 Produktion von EHEC O103:H2 und O111:H- nicht nur von EcN, sondern auch von E. coli K-12 Stamm MG1655, gehemmt wurde, im Gegensatz zur EcN-spezifischen Blockierung der Stx2-Produktion in den Serotypen O104:H4, O26:H11, O145:H25. Die Reduktion der Stx-Produktion in EAHEC O104:H4 TY3730 und TY3456, sowie EHEC O26:H11 war zum Teil von der Mikrozinproduktion abhängig. Diese hatte jedoch keinen Einfluss auf die Stx-Produktion in EHEC O157:H7 EDL933 und EHEC O145:H25. Bei Verwendung von LB-Medium zeigte sich im Gegensatz zum DMEM-Medium keine Mikrozin-Abhängigkeit der Toxinproduktion bei den EAHEC Isolaten TY3730 und TY3456. Die Toxinproduktion von EHEC EDL933 wurde ebenfalls nicht durch die Deletion der Mikrozin-Gene in EcN beeinflusst. Studien der Toxinproduktion in SCEM-Medium zeigten ebenfalls eine EcN-Dosisabhängige Reduktion der Stx-Produktion in Co-Kultur. Um den Mechanismus der Hemmung der Stx-Produktion zu untersuchen, wurden Versuche mit der EcN-Mutante EcN::luxS durchgeführt. Diese Deletion des AI-2 ´Quorum sensing´ Moleküls in EcN hatte allerdings keinen Einfluss auf die Hemmung der Stx-Produktion. Der Einsatz von Acetat führte, im Gegensatz zu publizierten Ergebnissen, nicht zu einer Reduktion der Stx-Produktion. Auch eine Beeinflussung der Lyse der EHEC-Bakterien, oder der Verminderung der Sekretion von Shiga Toxin durch EcN, konnte widerlegt werden. Zur Untersuchung der Stx-Expression wurde ein Assay mit einem biolumineszenten C-P (Chromosom-Plasmid) Reporter System etabliert. Damit konnte die Shiga Toxin Expression im Stammhintergrund EHEC EDL933 in Echtzeit untersucht werden. Hier wurde wiederum eine Reduktion der Shiga Toxin Expression in Co-Kultur mit EcN erfolgreich nachgewiesen.
In weiteren Versuchen konnte gezeigt werden, dass EcN nicht nur die Shiga Toxin Produktion von nicht-induzierten EAHEC Bakterien, sondern auch in mit Mitomycin C induzierten Bakterien hemmt.
Als wichtiger Sicherheitsaspekt einer Behandlung mit EcN wurde die Resistenz von EcN gegenüber Shiga Toxin Phagen untersucht. Die Infektion der Bakterien wurde hierbei mit stx-spezifischer PCR, Phagen-Plaque-Assay, Stx-ELISA und K+-Efflux Assay untersucht. Es konnte durch diese verschiedenen Methoden erfolgreich gezeigt werden, dass EcN nicht durch Shiga Toxin Phagen infiziert wird. Als möglicher Resistenzmechanismus kommt hier eine Mutation vom Phagenrezeptor LamB in Frage, was jedoch noch bestätigt werden muss.
Zusammenfassend wurden in dieser Arbeit wichtige antagonistische Effekte von EcN auf pathogene E. coli Stämme untersucht, die als Grundlage von neuen und dringend benötigten Behandlungen von EHEC-Infektionen dienen können.
Desert ants of the genus Cataglyphis have become model systems for the study of insect navigation. An age-related polyethism subdivides their colonies into interior workers and short-lived light-exposed foragers. While foraging in featureless and cluttered terrain over distances up to several hundred meters, the ants are able to precisely return back to their often inconspicuous nest entrance. They accomplish this enormous navigational performance by using a path integration system - including a polarization compass and an odometer - as their main navigational means in addition to landmark-dependent orientation and olfactory cues. C. fortis, being the focus of the present thesis, is endemic to the salt flats of western North Africa, which are completely avoided by other Cataglyphis species. The fact that Cataglyphis ants undergo a behavioral transition associated with drastically changing sensory demands makes these ants particularly interesting for studying synaptic plasticity in visual and olfactory brain centers. This thesis focuses on plastic changes in the mushroom bodies (MBs) - sensory integration centers supposed to be involved in learning and memory presumably including landmark learning - and in synaptic complexes belonging to the lateral accessory lobe (LAL) known to be a relay station in the polarization processing pathway. To investigate structural synaptic plasticity in the MBs of C. fortis, synaptic complexes (microglomeruli, MG) in the visual (collar) and olfactory (lip) input regions of the MB calyx were immunolabeled and their pre- and postsynaptic profiles were quantified. The results show that a volume increase of the MB calyx during behavioral transition is associated with a decrease of MG number - an effect called pruning - in the collar and, less pronounced, in the lip that goes along with dendritic expansion in MB intrinsic Kenyon cells. Light-exposure of dark-reared ants of different age classes revealed similar effects and dark-reared ants age-matched to foragers had MG numbers comparable to those of interior workers. The results indicate that the enormous structural synaptic plasticity of the MB calyx collar is primarily driven by visual experience rather than by an internal program. Ants aged artificially for up to one year expressed a similar plasticity indicating that the system remains flexible over the entire life-span. To investigate whether light-induced synaptic reorganization is reversible, experienced foragers were transferred back to darkness with the result that their MBs exhibit only some reverse-type characteristics, in particular differences in presynaptic synapsin expression. To investigate the structure of large synaptic complexes in the LAL of C. fortis and to detect potential structural changes, pre- and postsynaptic profiles in interior workers and foragers were immunolabeled and quantified by using confocal imaging and 3D-reconstruction. The results show that these complexes consist of postsynaptic processes located in a central region that is surrounded by a cup-like presynaptic profile. Tracer injections identified input and output tracts of the LAL: projection neurons from the anterior optic tubercle build connections with neurons projecting to the central complex. The behavioral transition is associated with an increase by ~13% of synaptic complexes suggesting that the polarization pathway may undergo some sort of calibration process. The structural features of these synaptic contacts indicate that they may serve a fast and reliable signal transmission in the polarization vision pathway. Behavioral analyses of C. fortis in the field revealed that the ants perform exploration runs including pirouette-like turns very close to the nest entrance for a period of up to two days, before they actually start their foraging activity. During these orientation runs the ants gather visual experience and might associate the nest entrance with specific landmarks or get entrained to other visual information like the polarization pattern, and, concomitantly adapt their neuronal circuitries to the upcoming challenges. Moreover, the pirouettes may serve to stimulate and calibrate the neuronal networks involved in the polarization compass pathway. Video recordings and analyses demonstrate that light experience enhanced the ants’ locomotor activity after three days of exposure. The fact that both the light-induced behavioral and neuronal changes in visual brain centers occur in the same time frame suggests that there may be a link between structural synaptic plasticity and the behavioral transition from interior tasks to outdoor foraging. Desert ants of the genus Cataglyphis possess remarkable visual navigation capabilities, but also employ olfactory cues for detecting nest and food sites. Using confocal imaging and 3D-reconstruction, potential adaptations in primary olfactory brain centers were analyzed by comparing the number, size and spatial arrangement of olfactory glomeruli in the antennal lobe of C. fortis, C. albicans, C. bicolor, C. rubra, and C. noda. Workers of all Cataglyphis species have smaller numbers of glomeruli compared to those of more olfactory-guided Formica species - a genus closely related to Cataglyphis - and to those previously found in other olfactory-guided ant species. C. fortis has the lowest number of glomeruli compared to all other species, but possesses a conspicuously enlarged glomerulus that is located close to the antennal nerve entrance. Males of C. fortis have a significantly smaller number of glomeruli compared to female workers and queens and a prominent male-specific macroglomerulus likely to be involved in sex pheromone communication. The behavioral significance of the enlarged glomerulus in female workers remains elusive. The fact that C. fortis inhabits microhabitats that are avoided by all other Cataglyphis species suggests that extreme ecological conditions may not only have resulted in adaptations of visual capabilities, but also in specializations of the olfactory system. The present thesis demonstrates that Cataglyphis is an excellent candidate for studying the neuronal mechanisms underlying navigational features and for studying neuronal plasticity associated with the ant’s lifelong flexibility of individual behavioral repertoires.
Protein kinases as targets for the development of novel drugs against alveolar echinococcosis
(2015)
The metacestode larval stage of the fox tapeworm Echinococcus multilocularis is the causative agent of alveolar echinococcosis (AE), one of the most lethal zoonosis of the northern hemisphere. The development of metacestode vesicles by asexual multiplication and the almost unrestricted infiltrative growth within the host organs is ensured from a population of undifferentiated, proliferative cells, so-called germinative cells. AE treatment options include surgery, if possible, as well as Benzimidazole-based chemotherapy (BZ). Given that the cellular targets of BZs, the -tubulins, are highly conserved between cestodes and humans, the chemotherapy is associated with considerable side-effects. Therefore, BZ can only be applied in parasitostatic doses and has to be given lifelong. Furthermore, the current anti-AE chemotherapy is ineffective in eliminating the germinative cell population of the parasite, which leads to remission of parasite growth as soon as therapy is discontinued.
This work focuses on protein kinases involved in the proliferation and development of the parasite with the intention of developing novel anti-AE therapies. Polo-like kinases (Plks) are important regulators of the eukaryotic cell cycle and are involved in the regulation and formation of the mitotic spindles during the M-phase of the cell cycle. Plks have already been shown to be associated with deregulated cellular growth in human cancers and have been investigated as novel drug targets in the flatworm parasite Schistosoma mansoni. In the first part of this work, the characterisation of a novel and druggable parasite enzyme, EmPlk1, which is homologous to the polo-like kinase 1 (Plk1) of humans and S. mansoni (SmPlk1), is presented. Through in situ hybridisation, it could be demonstrated that emplk1 is specifically expressed in the Echinococcus germinative cells. Upon heterologous expression in the Xenopus oocyte system, EmPlk1 induced germinal vesicle breakdown, thus indicating that it is an active kinase. Furthermore, BI 2536, a compound originally designed to inhibit the human ortholog of EmPlk1, inhibited the EmPlk1 activity at a concentration of 25 nM. In vitro treatment of parasite vesicles with similar concentrations of BI 2536 led to the elimination of the germinative cells from Echinococcus larvae, thus preventing the growth and further development of the parasite. In in vitro cultivation systems for parasite primary cells, BI 2536 effectively inhibited the formation of new metacestode vesicles from germinative cells. Thus, BI 2536 has profound anti-parasitic activities in vitro at concentrations well within the range of plasma levels measured after the administration of safe dosages to patients (50 nM after 24 h). This implies that EmPlk1 is a promising new drug target for the development of novel anti-AE drugs that would specifically affect the parasite’s stem cell population, namely the only parasite cells capable of proliferation. In addition to the chemotherapeutic aspects of this work, the inhibitor BI 2536 could be further used to study the function of stem cells in this model organism, utilising a method of injection of parasite stem cells into metacestode vesicles, for instance, as has been developed in this work.
In the second part of this work, a novel receptor tyrosine kinase, the Venus flytrap kinase receptor (EmVKR) of E. multilocularis has been characterised. Members of this class of single-pass transmembrane receptors have recently been discovered in the related trematode S. mansoni and are associated with the growth and differentiation of sporocyst germinal cells and ovocytes. The ortholog receptor in EmVKR is characterised by an unusual domain composition of an extracellular Venus flytrap module (VFT), which shows significant similarity to GABA receptors, such as the GABAB receptor (γ-amino butyric acid type B) and is linked through a single transmembrane domain to an intracellular tyrosine kinase domain with similarities to the kinase domains of human insulin receptors. Based upon the size (5112bp) of emvkr and nucleotide sequence specificities, efforts have been made to isolate the gene from cell culture samples to study the ligand for the activation of this receptor type in Xenopus oocytes. To date, this type of receptor has only been described in invertebrates, thus making it an attractive target for drug screening. In a first trial, the ATP competitive inhibitor AG 1024 was tested in our in vitro cell culture.
In conclusion, the EmVKR represents a novel receptor tyrosine kinase in E. multilocularis. Further efforts have to be made to identify the activating ligand of the receptor and its cellular function, which might strengthen the case for EmVKR as a potential drug target. The successful depletion of stem cells in the metacestode vesicle by the Plk1 inhibitor BI 2536 gives rise to optimising the chemical component for EmPlk1 as a new potential drug target. Furthermore, this inhibitor opens a new cell culture technique with high potential to study the cellular behaviour and influencing factors of stem cells in vitro.
Alle Retroviren prozessieren ihre Pol- und Strukturproteine mit Hilfe der viralen Protease. In dieser Arbeit wurden zentrale Mechanismen der Regulation der foamyviralen Protease untersucht und charakterisiert. Dazu wurde eine chromatographische Virusreinigungsmethode entwickelt und die relative Pol- und Env-Enkapsidierung bestimmt. Foamyviren enthalten weniger Pol als andere Retroviren aber deutlich mehr Env als humane Immunodefizienzviren. Die Pol-Inkorporation könnte durch die limitierte Prozessierung mit nur einer einzigen Schnittstelle in Gag und Pol kompensiert werden. Deshalb wurde untersucht, ob die foamyvirale Protease ein beschränktes Schnittstellenrepertoire aufweist. In Zellkulturen sind die Schnitt-stellenpositionen P2’ und P2 auf die Aminosäurereste Valin und Valin/Asparagin beschränkt. Demnach hat die foamyvirale Protease ein eingeschränkteres Schnittstellenrepertoire als die Protease des humanen Immunodefizienzvirus. Weiterhin wurde hier gezeigt, dass die vollständige reverse Transkription die Prozessierung von Gag voraussetzt und Proteaseaktivität-defiziente oder Gag-Schnittstellen-defiziente Viren keine vollständige cDNA bilden können. Demnach kompensieren Foamyviren die niedrige Proteasekonzentration, indem sie sicherstellen, dass die reverse Transkription erst nach der Gag-Maturation vollendet werden kann.
Weiterhin wird bei humanen Immunodefizienzviren durch die Gag-Maturation die essenzielle Mobilität der wenigen Env-Trimere auf der Hüllmembran getriggert. Die erstmals in dieser Arbeit bei Foamyviren quantifizierte Env-Menge ergab, dass Foamyviren 28 mal mehr Env- pro Gag-Molekül als humane Immunodefizienzviren besitzen. Wahrscheinlich dient dieser hohe Env-Gehalt der Kompensation der eingeschränkten Env-Mobilität, die durch die limitierte Gag-Prozessierung an nur einer carboxyterminalen Schnittstelle verursacht wird.
Da für die Aktivierung der foamyviralen Protease virale Ribonukleinsäure benötigt wird, wurde untersucht, welche Pol-Domänen für die Aktivierung der Protease benötigt werden. Im Gegensatz zur Integrase, deren Deletion in reduzierter Proteaseaktivität resultierte, war die funktionelle RNaseH-Domäne essenziell für die Gag-Prozessierung. Die Substitution der foamyviralen RNaseH durch RNaseH-Domänen von anderen Retroviren resultierte in genomunabhängiger Proteaseaktivität in Zellen und genomabhängiger Proteaseaktivität in den rekombinanten Viren. Demnach scheint die dimerstabilisierende Funktion der RNaseH durch direkte Protein-Protein-Interaktion oder durch unspezifische RNA-Bindung verursacht zu werden.
In this work we wanted to investigate the role of NFATc1 in lymphocyte physiology and in pathological conditions (eg. psoriasis). NFATc1 is part of the signal transduction
pathways that regulates B cells activation and function. NFATc1 has different isoforms that are due to different promoters (P1 and P2), polyadenylation and alternative splicing. Moreover, we tried to elucidate the points of interactions between the NFAT and the NF-κB pathways in
activated B-cell fate. NFAT and NF-κB factors share several properties, such as a similar mode of induction and architecture in their DNA binding domain. We used mice which over-express a constitutive active version of NFATc1/α in their B cells with -or without- an ablated IRF4. IRF4 inhibits cell cycle progression of germinal center B cell-derived Burkitt’s lymphoma cells and
induces terminal differentiation toward plasma cells. Our experiments showed that a ‘double hit’ in factors affecting B cell activation (NFATc1 in this case) and late B cell Differentiation (IRF4 in this case) alter the development of the B cells, lead to increase in their numbers and increase in stimulation induced proliferation. Therefore, the overall picture indicates a link between these 2 genes and probable carcinogenic alterations that may occur in B cells.
We also show that in splenic B cells, c-Rel (of the NF-κB canonical pathway) Support the induction of NFATc1/αA through BCR signals. We also found evidence that the lack of NFATc1 affects the expression of Rel-B (of the NF-κB non-canonical pathway). These data suggest a tight interplay between NFATc1 and NF-κB in B cells, influencing the competence of B cells and their functions in peripheral tissues.
We also used IMQ-induced psoriasis-like inflammation on mice which either lack NFATc1 from B cell. Psoriasis is a systemic chronic immunological disease characterized
primarily by abnormal accelerated proliferation of the skin keratinocytes. In psoriasis, the precipitating event leads to immune cell activation. Our experiments showed that NFATc1 is needed for the development of psoriasis. It also showed that IL-10 is the link that enables NFAT
from altering the B cell compartment (eg Bregs) in order to affect inflammation. The important role of B cell in psoriasis is supported by the flared up psoriasis-like inflammation in mice that lack B cells. Bregs is a special type of B cells that regulate other B cells and T cells; tuning the immunological response through immunomodulatory cytokines.
The learned helplessness phenomenon is a specific animal behavior induced by prior exposure to uncontrollable aversive stimuli. It was first found by Seligman and Maier (1967) in dogs and then has been reported in many other species, e.g. in rats (Vollmayr and Henn, 2001), in goldfishes (Padilla, 1970), in cockroaches (Brown, 1988) and also in fruit flies (Brown, 1996; Bertolucci, 2008). However, the learned helplessness effect in fruit flies (Drosophila melanogaster) has not been studied in detail. Thus, in this doctoral study, we investigated systematically learned helplessness behavior of Drosophila for the first time.
Three groups of flies were tested in heatbox. Control group was in the chambers experiencing constant, mild temperature. Second group, master flies were punished in their chambers by being heated if they stopped walking for 0.9s. The heat pulses ended as soon as they resumed walking again. A third group, the yoked fly, was in their chambers at the same time. However, their behavior didn’t affect anything: yoked flies were heated whenever master flies did, with same timing and durations. After certain amount of heating events, yoked flies associated their own behavior with the uncontrollability of the environment. They suppressed their innate responses such as reducing their walking time and walking speed; making longer escape latencies and less turning around behavior under heat pulses. Even after the conditioning phase, yoked flies showed lower activity level than master and control flies. Interestingly, we have also observed sex dimorphisms in flies. Male flies expressed learned helplessness not like female flies. Differences between master and yoked flies were smaller in male than in female flies. Another interesting finding was that prolonged or even repetition of training phases didn’t enhance learned helplessness effect in flies.
Furthermore, we investigated serotonergic and dopaminergic nervous systems in learned helplessness. Using genetic and pharmacological manipulations, we altered the levels of serotonin and dopamine in flies’ central nervous system. Female flies with reduced serotonin concentration didn’t show helpless behavior, while the learned helplessness effect in male flies seems not to be affected by a reduction of serotonin. Flies with lower dopamine level do not display the learned helplessness effect in the test phase, suggesting that with low dopamine the motivational change in learned helplessness in Drosophila may decline faster than with a normal dopamine level.